Source link : https://www.newshealth.biz/health-news/fda-approves-new-esophageal-cancer-drug/
The US Food and Drug Administration (FDA) has approved tislelizumab-jsgr (Tevimbra, BeiGene, Ltd.) as second-line monotherapy for certain adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC). Specifically, the novel checkpoint inhibitor is approved for patients with ESCC after prior systemic chemotherapy that did not include a programmed death–ligand 1 (PD-L1) inhibitor. Approval […]
Author : News Health
Publish date : 2024-03-14 22:42:47
Copyright for syndicated content belongs to the linked Source.
in Health